Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3(+) CD8(+) T Cells and Survival in Diffuse Large B Cell Lymphoma

Tim-3 is a promising target for antitumor immunotherapy. A number of clinical trials are evaluating the efficacy of anti-Tim-3 therapies as a single agent or combinations in solid tumors and haematologic malignancies. However, there remains a considerable lack of data on Tim-3 signalling, especially...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Tingting, Ren, Tianyuan, Song, Zheng, Zhao, Jing, Jiao, Lei, Zhang, Zhenzhen, He, Jin, Liu, Xianming, Qiu, Lihua, Li, Lanfang, Zhou, Shiyong, Meng, Bin, Zhai, Qiongli, Ren, Xiubao, Qian, Zhengzi, Wang, Xianhuo, Zhang, Huilai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7647777/
https://www.ncbi.nlm.nih.gov/pubmed/33178839
http://dx.doi.org/10.1155/2020/6968595

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7647777/
https://www.ncbi.nlm.nih.gov/pubmed/33178839
http://dx.doi.org/10.1155/2020/6968595

Ejemplares similares